0
     

Report Added
Report already added
Global T-Cell Immunotherapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global T-Cell Immunotherapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028

The T-Cell Immunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global T-Cell Immunotherapy market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Stomach Cancer accounting for % of the T-Cell Immunotherapy global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While CAR-T segment is altered to a % CAGR between 2022 and 2028.
Global key companies of T-Cell Immunotherapy include Adaptimmune, Altor Bioscience Corporation, Cellectis, Juno Therapeutics, and Kite Pharma, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation
T-Cell Immunotherapy market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
CAR-T
TCR
TIL Therapies
Market segment by Application, can be divided into
Stomach Cancer
Lung Cancer
Colorectal Cancer
Esophagus Cancer
Pancreatic Cancer
Others
Market segment by players, this report covers
Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Kite Pharma
Novartis
Takara Bio
Unum Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe T-Cell Immunotherapy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of T-Cell Immunotherapy, with revenue, gross margin and global market share of T-Cell Immunotherapy from 2019 to 2022.
Chapter 3, the T-Cell Immunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and T-Cell Immunotherapy market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe T-Cell Immunotherapy research findings and conclusion, appendix and data source.
Table of Contents

1 Market Overview
1.1 Product Overview and Scope of T-Cell Immunotherapy
1.2 Classification of T-Cell Immunotherapy by Type
1.2.1 Overview: Global T-Cell Immunotherapy Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global T-Cell Immunotherapy Revenue Market Share by Type in 2021
1.2.3 CAR-T
1.2.4 TCR
1.2.5 TIL Therapies
1.3 Global T-Cell Immunotherapy Market by Application
1.3.1 Overview: Global T-Cell Immunotherapy Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Stomach Cancer
1.3.3 Lung Cancer
1.3.4 Colorectal Cancer
1.3.5 Esophagus Cancer
1.3.6 Pancreatic Cancer
1.3.7 Others
1.4 Global T-Cell Immunotherapy Market Size & Forecast
1.5 Global T-Cell Immunotherapy Market Size and Forecast by Region
1.5.1 Global T-Cell Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global T-Cell Immunotherapy Market Size by Region, (2017-2022)
1.5.3 North America T-Cell Immunotherapy Market Size and Prospect (2017-2028)
1.5.4 Europe T-Cell Immunotherapy Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific T-Cell Immunotherapy Market Size and Prospect (2017-2028)
1.5.6 South America T-Cell Immunotherapy Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa T-Cell Immunotherapy Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 T-Cell Immunotherapy Market Drivers
1.6.2 T-Cell Immunotherapy Market Restraints
1.6.3 T-Cell Immunotherapy Trends Analysis
2 Company Profiles
2.1 Adaptimmune
2.1.1 Adaptimmune Details
2.1.2 Adaptimmune Major Business
2.1.3 Adaptimmune T-Cell Immunotherapy Product and Solutions
2.1.4 Adaptimmune T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Adaptimmune Recent Developments and Future Plans
2.2 Altor Bioscience Corporation
2.2.1 Altor Bioscience Corporation Details
2.2.2 Altor Bioscience Corporation Major Business
2.2.3 Altor Bioscience Corporation T-Cell Immunotherapy Product and Solutions
2.2.4 Altor Bioscience Corporation T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Altor Bioscience Corporation Recent Developments and Future Plans
2.3 Cellectis
2.3.1 Cellectis Details
2.3.2 Cellectis Major Business
2.3.3 Cellectis T-Cell Immunotherapy Product and Solutions
2.3.4 Cellectis T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Cellectis Recent Developments and Future Plans
2.4 Juno Therapeutics
2.4.1 Juno Therapeutics Details
2.4.2 Juno Therapeutics Major Business
2.4.3 Juno Therapeutics T-Cell Immunotherapy Product and Solutions
2.4.4 Juno Therapeutics T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Juno Therapeutics Recent Developments and Future Plans
2.5 Kite Pharma
2.5.1 Kite Pharma Details
2.5.2 Kite Pharma Major Business
2.5.3 Kite Pharma T-Cell Immunotherapy Product and Solutions
2.5.4 Kite Pharma T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Kite Pharma Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis T-Cell Immunotherapy Product and Solutions
2.6.4 Novartis T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Takara Bio
2.7.1 Takara Bio Details
2.7.2 Takara Bio Major Business
2.7.3 Takara Bio T-Cell Immunotherapy Product and Solutions
2.7.4 Takara Bio T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Takara Bio Recent Developments and Future Plans
2.8 Unum Therapeutics
2.8.1 Unum Therapeutics Details
2.8.2 Unum Therapeutics Major Business
2.8.3 Unum Therapeutics T-Cell Immunotherapy Product and Solutions
2.8.4 Unum Therapeutics T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Unum Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global T-Cell Immunotherapy Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 T-Cell Immunotherapy Players Market Share in 2021
3.2.2 Top 10 T-Cell Immunotherapy Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 T-Cell Immunotherapy Players Head Office, Products and Services Provided
3.4 T-Cell Immunotherapy Mergers & Acquisitions
3.5 T-Cell Immunotherapy New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global T-Cell Immunotherapy Revenue and Market Share by Type (2017-2022)
4.2 Global T-Cell Immunotherapy Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global T-Cell Immunotherapy Revenue Market Share by Application (2017-2022)
5.2 Global T-Cell Immunotherapy Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America T-Cell Immunotherapy Revenue by Type (2017-2028)
6.2 North America T-Cell Immunotherapy Revenue by Application (2017-2028)
6.3 North America T-Cell Immunotherapy Market Size by Country
6.3.1 North America T-Cell Immunotherapy Revenue by Country (2017-2028)
6.3.2 United States T-Cell Immunotherapy Market Size and Forecast (2017-2028)
6.3.3 Canada T-Cell Immunotherapy Market Size and Forecast (2017-2028)
6.3.4 Mexico T-Cell Immunotherapy Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe T-Cell Immunotherapy Revenue by Type (2017-2028)
7.2 Europe T-Cell Immunotherapy Revenue by Application (2017-2028)
7.3 Europe T-Cell Immunotherapy Market Size by Country
7.3.1 Europe T-Cell Immunotherapy Revenue by Country (2017-2028)
7.3.2 Germany T-Cell Immunotherapy Market Size and Forecast (2017-2028)
7.3.3 France T-Cell Immunotherapy Market Size and Forecast (2017-2028)
7.3.4 United Kingdom T-Cell Immunotherapy Market Size and Forecast (2017-2028)
7.3.5 Russia T-Cell Immunotherapy Market Size and Forecast (2017-2028)
7.3.6 Italy T-Cell Immunotherapy Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific T-Cell Immunotherapy Revenue by Type (2017-2028)
8.2 Asia-Pacific T-Cell Immunotherapy Revenue by Application (2017-2028)
8.3 Asia-Pacific T-Cell Immunotherapy Market Size by Region
8.3.1 Asia-Pacific T-Cell Immunotherapy Revenue by Region (2017-2028)
8.3.2 China T-Cell Immunotherapy Market Size and Forecast (2017-2028)
8.3.3 Japan T-Cell Immunotherapy Market Size and Forecast (2017-2028)
8.3.4 South Korea T-Cell Immunotherapy Market Size and Forecast (2017-2028)
8.3.5 India T-Cell Immunotherapy Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia T-Cell Immunotherapy Market Size and Forecast (2017-2028)
8.3.7 Australia T-Cell Immunotherapy Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America T-Cell Immunotherapy Revenue by Type (2017-2028)
9.2 South America T-Cell Immunotherapy Revenue by Application (2017-2028)
9.3 South America T-Cell Immunotherapy Market Size by Country
9.3.1 South America T-Cell Immunotherapy Revenue by Country (2017-2028)
9.3.2 Brazil T-Cell Immunotherapy Market Size and Forecast (2017-2028)
9.3.3 Argentina T-Cell Immunotherapy Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa T-Cell Immunotherapy Revenue by Type (2017-2028)
10.2 Middle East & Africa T-Cell Immunotherapy Revenue by Application (2017-2028)
10.3 Middle East & Africa T-Cell Immunotherapy Market Size by Country
10.3.1 Middle East & Africa T-Cell Immunotherapy Revenue by Country (2017-2028)
10.3.2 Turkey T-Cell Immunotherapy Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia T-Cell Immunotherapy Market Size and Forecast (2017-2028)
10.3.4 UAE T-Cell Immunotherapy Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global T-Cell Immunotherapy Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global T-Cell Immunotherapy Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market T-Cell Immunotherapy Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global T-Cell Immunotherapy Revenue (USD Million) by Region (2017-2022)
Table 5. Global T-Cell Immunotherapy Revenue Market Share by Region (2023-2028)
Table 6. Adaptimmune Corporate Information, Head Office, and Major Competitors
Table 7. Adaptimmune Major Business
Table 8. Adaptimmune T-Cell Immunotherapy Product and Solutions
Table 9. Adaptimmune T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Altor Bioscience Corporation Corporate Information, Head Office, and Major Competitors
Table 11. Altor Bioscience Corporation Major Business
Table 12. Altor Bioscience Corporation T-Cell Immunotherapy Product and Solutions
Table 13. Altor Bioscience Corporation T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Cellectis Corporate Information, Head Office, and Major Competitors
Table 15. Cellectis Major Business
Table 16. Cellectis T-Cell Immunotherapy Product and Solutions
Table 17. Cellectis T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Juno Therapeutics Corporate Information, Head Office, and Major Competitors
Table 19. Juno Therapeutics Major Business
Table 20. Juno Therapeutics T-Cell Immunotherapy Product and Solutions
Table 21. Juno Therapeutics T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Kite Pharma Corporate Information, Head Office, and Major Competitors
Table 23. Kite Pharma Major Business
Table 24. Kite Pharma T-Cell Immunotherapy Product and Solutions
Table 25. Kite Pharma T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Novartis Corporate Information, Head Office, and Major Competitors
Table 27. Novartis Major Business
Table 28. Novartis T-Cell Immunotherapy Product and Solutions
Table 29. Novartis T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Takara Bio Corporate Information, Head Office, and Major Competitors
Table 31. Takara Bio Major Business
Table 32. Takara Bio T-Cell Immunotherapy Product and Solutions
Table 33. Takara Bio T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Unum Therapeutics Corporate Information, Head Office, and Major Competitors
Table 35. Unum Therapeutics Major Business
Table 36. Unum Therapeutics T-Cell Immunotherapy Product and Solutions
Table 37. Unum Therapeutics T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Global T-Cell Immunotherapy Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 39. Global T-Cell Immunotherapy Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 40. Breakdown of T-Cell Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. T-Cell Immunotherapy Players Head Office, Products and Services Provided
Table 42. T-Cell Immunotherapy Mergers & Acquisitions in the Past Five Years
Table 43. T-Cell Immunotherapy New Entrants and Expansion Plans
Table 44. Global T-Cell Immunotherapy Revenue (USD Million) by Type (2017-2022)
Table 45. Global T-Cell Immunotherapy Revenue Share by Type (2017-2022)
Table 46. Global T-Cell Immunotherapy Revenue Forecast by Type (2023-2028)
Table 47. Global T-Cell Immunotherapy Revenue by Application (2017-2022)
Table 48. Global T-Cell Immunotherapy Revenue Forecast by Application (2023-2028)
Table 49. North America T-Cell Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 50. North America T-Cell Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 51. North America T-Cell Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 52. North America T-Cell Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 53. North America T-Cell Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 54. North America T-Cell Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 55. Europe T-Cell Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 56. Europe T-Cell Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 57. Europe T-Cell Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 58. Europe T-Cell Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 59. Europe T-Cell Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 60. Europe T-Cell Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 61. Asia-Pacific T-Cell Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 62. Asia-Pacific T-Cell Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 63. Asia-Pacific T-Cell Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 64. Asia-Pacific T-Cell Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 65. Asia-Pacific T-Cell Immunotherapy Revenue by Region (2017-2022) & (USD Million)
Table 66. Asia-Pacific T-Cell Immunotherapy Revenue by Region (2023-2028) & (USD Million)
Table 67. South America T-Cell Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 68. South America T-Cell Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 69. South America T-Cell Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 70. South America T-Cell Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 71. South America T-Cell Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 72. South America T-Cell Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 73. Middle East & Africa T-Cell Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 74. Middle East & Africa T-Cell Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 75. Middle East & Africa T-Cell Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 76. Middle East & Africa T-Cell Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 77. Middle East & Africa T-Cell Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 78. Middle East & Africa T-Cell Immunotherapy Revenue by Country (2023-2028) & (USD Million)

List of Figures
Figure 1. T-Cell Immunotherapy Picture
Figure 2. Global T-Cell Immunotherapy Revenue Market Share by Type in 2021
Figure 3. CAR-T
Figure 4. TCR
Figure 5. TIL Therapies
Figure 6. T-Cell Immunotherapy Revenue Market Share by Application in 2021
Figure 7. Stomach Cancer Picture
Figure 8. Lung Cancer Picture
Figure 9. Colorectal Cancer Picture
Figure 10. Esophagus Cancer Picture
Figure 11. Pancreatic Cancer Picture
Figure 12. Others Picture
Figure 13. Global T-Cell Immunotherapy Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 14. Global T-Cell Immunotherapy Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global T-Cell Immunotherapy Revenue Market Share by Region (2017-2028)
Figure 16. Global T-Cell Immunotherapy Revenue Market Share by Region in 2021
Figure 17. North America T-Cell Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Europe T-Cell Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Asia-Pacific T-Cell Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. South America T-Cell Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Middle East and Africa T-Cell Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. T-Cell Immunotherapy Market Drivers
Figure 23. T-Cell Immunotherapy Market Restraints
Figure 24. T-Cell Immunotherapy Market Trends
Figure 25. Adaptimmune Recent Developments and Future Plans
Figure 26. Altor Bioscience Corporation Recent Developments and Future Plans
Figure 27. Cellectis Recent Developments and Future Plans
Figure 28. Juno Therapeutics Recent Developments and Future Plans
Figure 29. Kite Pharma Recent Developments and Future Plans
Figure 30. Novartis Recent Developments and Future Plans
Figure 31. Takara Bio Recent Developments and Future Plans
Figure 32. Unum Therapeutics Recent Developments and Future Plans
Figure 33. Global T-Cell Immunotherapy Revenue Share by Players in 2021
Figure 34. T-Cell Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players T-Cell Immunotherapy Revenue Market Share in 2021
Figure 36. Global Top 10 Players T-Cell Immunotherapy Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global T-Cell Immunotherapy Revenue Share by Type in 2021
Figure 39. Global T-Cell Immunotherapy Market Share Forecast by Type (2023-2028)
Figure 40. Global T-Cell Immunotherapy Revenue Share by Application in 2021
Figure 41. Global T-Cell Immunotherapy Market Share Forecast by Application (2023-2028)
Figure 42. North America T-Cell Immunotherapy Sales Market Share by Type (2017-2028)
Figure 43. North America T-Cell Immunotherapy Sales Market Share by Application (2017-2028)
Figure 44. North America T-Cell Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 45. United States T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe T-Cell Immunotherapy Sales Market Share by Type (2017-2028)
Figure 49. Europe T-Cell Immunotherapy Sales Market Share by Application (2017-2028)
Figure 50. Europe T-Cell Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 51. Germany T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific T-Cell Immunotherapy Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific T-Cell Immunotherapy Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific T-Cell Immunotherapy Revenue Market Share by Region (2017-2028)
Figure 59. China T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America T-Cell Immunotherapy Sales Market Share by Type (2017-2028)
Figure 66. South America T-Cell Immunotherapy Sales Market Share by Application (2017-2028)
Figure 67. South America T-Cell Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 68. Brazil T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa T-Cell Immunotherapy Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa T-Cell Immunotherapy Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa T-Cell Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 73. Turkey T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source

Report Title: Global T-Cell Immunotherapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update